Lupin names Rakesh Bhardwaj as Chief Information Officer

Published On 2024-03-10 08:00 GMT   |   Update On 2024-03-10 08:01 GMT

Mumbai: Global pharma major Lupin Limited has announced the appointment of Rakesh Bhardwaj as Chief Information Officer (CIO). He will be based in Mumbai and lead Lupin’s global Information Technology function and spearhead the company’s digital transformation.Rakesh brings to Lupin rich experience of over three decades in building and managing cutting edge global IT teams and systems...

Login or Register to read the full article

Mumbai: Global pharma major Lupin Limited has announced the appointment of Rakesh Bhardwaj as Chief Information Officer (CIO). He will be based in Mumbai and lead Lupin’s global Information Technology function and spearhead the company’s digital transformation.

Rakesh brings to Lupin rich experience of over three decades in building and managing cutting edge global IT teams and systems for some of the largest enterprises in the world. His last assignment was with Ola as Group Chief Information Officer, prior to which he has held leadership positions with Cognizant, Micro land, General Electric and BISIL. Rakesh holds a bachelor’s degree in Engineering in Computer Science from Gulbarga University, Karnataka.

Commenting on the appointment, Ramesh Swaminathan, Executive Director, Global CFO and Head – Corporate Affairs, Lupin said, “Information Technology plays a critical role in advancing and expanding our horizons as a global pharmaceutical leader. We are pleased to welcome Rakesh to Lupin, further enhancing our IT foundation. With his expertise, he will drive our efforts in digitalization, process automation, data management and analytics, all of which will reinforce Lupin’s position as a frontrunner in innovation and excellence within the industry.”

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.9% of its revenue in research and development in FY23. Lupin has 15 manufacturing sites, 7 research centers.

Read also: Lupin bags USFDA nod for pregnancy prevention drug Minzoya

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News